This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Counsel For Former Matria Healthcare Chairman And CEO Parker H. Petit Deny SEC Claims









ATLANTA, Jan. 11, 2012 /PRNewswire/ -- Attorneys for business executive and philanthropist Parker H. "Pete" Petit are calling on the Securities and Exchange Commission (SEC) to dismiss a civil complaint the Commission brought against Mr. Petit. 

The SEC has alleged that Mr. Petit provided information to a friend who made two purchases of Matria Healthcare stock in 2007.  The purchases occurred prior to the sale of Matria in 2008 to Inverness Medical Innovations, Inc.  (now known as Alere, Inc.) Mr. Petit was the Chairman and CEO of Matria.  Mr. Petit is not alleged to have received any money stemming from the friend's purchase.

Mr. Petit's legal counsel said that the Commission's case is without merit, and that Mr. Petit passed a polygraph test proving he did not provide inside information.  The polygraph was administered by a polygraph expert who is the FBI's former chief polygraph examiner and was previously used by the SEC itself.

"We gave the SEC the results of the expert's polygraph test as specific evidence that Mr. Petit was truthful in stating he did not provide inside information, and that the SEC's claims are groundless," said Aaron Danzig, of the law firm Arnall Golden Gregory.  Mr. Danzig, a former federal prosecutor, said that the Commission responded to Mr. Petit's polygraph results by requesting that Mr. Petit submit to a second polygraph conducted by the SEC.  Mr. Petit agreed, on the condition that the Commission declines any enforcement action when Mr. Petit passes the second test.  Rather than follow through on its request, the SEC instead chose to sue Mr. Petit.

The SEC's investigation was born out of a friendship between Earl Arrowood, a retired Delta Air Lines pilot, and Mr. Petit, who is also an experienced pilot, as both men fly together occasionally. The facts do not support the SEC's allegations that Mr. Petit passed inside information to Mr. Arrowood in October and December 2007: 

  • The complaint suggests that Mr. Petit passed inside information to Mr. Arrowood just prior to Mr. Arrowood's October 25, 2007 purchase of Matria stock. In fact, they had not spoken for two weeks nor flown together for almost three weeks prior to that date.  
  • In December 2007, Mr. Arrowood was assisting Mr. Petit in purchasing a newer airplane.  As a result, Mr. Petit and Mr. Arrowood had numerous telephone calls during December and January about aircrafts. Unbeknownst to Mr. Petit, Mr. Arrowood purchased Matria stock in December 2007.
  • During that same period, Matria's Board of Directors was exploring the possibilities of the sale of Matria.  On January 28, 2008, the Company publicly announced it was being acquired. 
  • Mr. Arrowood's profit from the sale of this stock six months after the announcement of the acquisition was $9,900, not $94,000 as alleged by the SEC.

"The SEC, in its zeal to prosecute a respected executive and philanthropist, has jumped to a false conclusion that Pete's relationship with Mr. Arrowood led to improper trading by Mr. Arrowood on inside information.  Nothing could be further from the truth," Danzig said.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs